Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Abstract Text:

Sheila K West,Beatriz Munoz,Harran Mkocha,Charlotte Gaydos,Thomas Quinn,

PURPOSE: The World Health Organization recommends mass treatment of trachoma-hyperendemic communities, but there are scant empiric data on the number of rounds of treatment that are necessary for sustainable reductions. The rates of active trachoma and infection with C. trachomatis were determined in a community 3.5 years after two rounds of mass treatment with azithromycin. METHODS: Maindi village in Tanzania received a first round of mass treatment with azithromycin after a baseline survey for trachoma and infection. All residents aged 6 months and older were offered single-dose treatment with azithromycin (excluding pregnant women with no clinical trachoma, who were offered topical tetracycline). The residents were followed over an 18-month period, and, according to similar treatment criteria, were offered retreatment at 18 months. Five years after baseline (3.5 years after the second round of mass treatment), a new census and survey of current residents for trachoma and infection was conducted. Children are the sentinel markers of infection and trachoma in communities, so data are presented specifically for ages 0 to 7 years (preschool age) and 8 to 16 years. RESULTS: Treatment coverage was above 80% for all ages in the first round, and highest (90%) in preschool-aged children. Second-round coverage was lower, <70%, and 70% in preschool-aged children. At 5 years, trachoma rates were still lower than baseline, ranging from 45% in those aged 0 to 3 years to 8% in those aged 11 to 15 years (compared with 81% and 39% at baseline, respectively). Infection rates at baseline ranged from 71% to 57%, but were 27% to 17% at 5 years after two rounds of mass treatment. At 5 years, there were no differences in trachoma or infection rates, when comparing new residents who came after the second mass treatment with those who had been resident in the village during both rounds (P > 0.05). Infection rates were lower in those who had been treated twice or at 18 months than in those treated only at baseline or never treated. CONCLUSIONS: Although mass treatment appears to be associated with lower disease and infection rates in the long term, trachoma and C. trachomatis infection were not eliminated in this trachoma hyperendemic village 3.5 years after two rounds of mass treatment. Continued implementation of the SAFE strategy in this environment is needed.

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Publishing Authors By Initials

SK West,B Munoz,H Mkocha,C Gaydos,T Quinn,

For similar bacterial infections and mycoses: bacterial infections: eye infections, bacterial: conjunctivitis, bacterial: trachoma research abstracts see: bacterial infections and mycoses: bacterial infections: eye infections, bacterial: conjunctivitis, bacterial: trachoma research

PUBMED ID PMID:

MEDLINE DATE:

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Investigative ophthalmology & visual science

VOLUME: 48

Page Numbers: 1492-7

Journal Abbreviation: Invest. Ophthalmol. Vis. Sci.

ISSN: 0146-0404

DAY: 3

MONTH: Apr

YEAR: 2007

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7703701

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Keywords Mesh Terms:

KEYWORDS: Trachoma

MESH TERMS: microbiology

Chemical & Substance for Abstract: Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Information

Substance Name: Azithromycin

Registry Number: 83905-01-5

Grant and Affiliation Information for Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.

AFFILIATION: Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, JHU Hospital, 600 N. Wolfe Street, Baltimore, MD 21205, USA. shwest@jhmi.edu

Country: United States

AGENCY: United States NEI

GRANT: EY 001765

ACRONYM: EY

MEDLINETA: Invest Ophthalmol Vis Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village Related Publications

• A role for eyebrows in regulating the visibility of eye gaze direction.
• Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging.
• Comments on the analysis of some triacid triglyceride mixtures.
• Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
• Contact Lenses in Pediatrics (CLIP) Study: chair time and ocular health.
• Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.
• Gender and cleaner production: toward a framework for including gender analysis when developing strategies and designing solutions.
• Generation of a transgenic model to address regulation and function of the human neurokinin 1 receptor (NK1R).
• High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
• Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
• Infants' sensitivity to uniform connectedness as a cue for perceptual organization.
• Melanoma imaging with pretargeted bivalent bacteriophage.
• N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase.
• Nitric oxide-NGF mediated PPTA/SP, ADNP, and VIP expression in the peripheral nervous system.
• Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.
• Passivating protein coatings for implantable glucose sensors: evaluation of protein retention.
• Pharmacological treatment of heart failure.
• Reducing health disparities in depressive disorders outcomes between non-Hispanic Whites and ethnic minorities: a call for pragmatic strategies over the life course.
• Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
• Retinopathy of prematurity in Brazil: an emerging problem.
• Review: advance provision of emergency contraception increases its use but does not reduce unplanned pregnancies.
• Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha.
• Spina bifida advocacy--a case study in public policy success.
• Systemic reaction rates to field stings among imported fire ant-sensitive patients receiving >3 years of immunotherapy versus <3 years of immunotherapy.
• The future in advanced prostate cancer: take your partners or is the last dance for me?
• The purification and specificity of a lipase fromVernonia anthelmintica seed.
• Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
• Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
• Trench entrapment: is ketamine safe to use for sedation in head injury?
• Uterine innervation in fibroids: a qualitative study.